SCLC · Oncology · 5 drugs · 5 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| rilvegostomig | AZN | PD-1 + TIGIT dual blockade | Bispecific | IV | PHASE3 |
| Ifinatamab deruxtecan | DSNKY, AZN | B7-H3-directed (DXd payload) | ADC | IV | PHASE3 |
| Tecentriq | ROG.SW | PD-L1 inhibitor | Antibody | IV | APPROVED |
| Imfinzi | AZN | PD-L1 inhibitor | Antibody | IV | APPROVED |
| IMDELLTRA | AMGN | DLL3-targeting BiTE (bispecific T-cell engager) | Bispecific T-cell engager (BiTE) | IV | APPROVED |